Abstract
Recently, significant progress has been made towards understanding the pathogenesis of cancer from the molecular standpoint. To this end, a growing number of approaches are being exploited for the identification and validation of new therapeutic targets suitable for potent and specific intervention. The type 1 insulin-like growth factor receptor (IGF-1R) system has recently become the focus of major attention in the arena of cancer research. The involvement of the receptor and its downstream signaling cascades in the carcinogenesis process makes this system an excellent target for potential cancer therapy. Indeed, advances in the understanding of the molecular mechanisms behind IGF-1R activation have led to the discovery of agents designed selectively for targeting IGF-1R. The potential application of these inhibitors is currently under intense clinical investigation. This review describes the biology of IGF-1R particularly from a cancer perspective. The attempts to develop effective IGF-1R antagonists are discussed comprehensively with special emphasis on antibodies and small tyrosine kinase inhibitors.
Keywords: Tumor growth, apoptosis, IGF-1R, RTK, antibody, TKI, cancer therapy
Combinatorial Chemistry & High Throughput Screening
Title: Targeted Therapy of the Insulin-Like Growth Factor-1 Receptor in Cancer
Volume: 11 Issue: 1
Author(s): Keren Paz and Yaron R. Hadari
Affiliation:
Keywords: Tumor growth, apoptosis, IGF-1R, RTK, antibody, TKI, cancer therapy
Abstract: Recently, significant progress has been made towards understanding the pathogenesis of cancer from the molecular standpoint. To this end, a growing number of approaches are being exploited for the identification and validation of new therapeutic targets suitable for potent and specific intervention. The type 1 insulin-like growth factor receptor (IGF-1R) system has recently become the focus of major attention in the arena of cancer research. The involvement of the receptor and its downstream signaling cascades in the carcinogenesis process makes this system an excellent target for potential cancer therapy. Indeed, advances in the understanding of the molecular mechanisms behind IGF-1R activation have led to the discovery of agents designed selectively for targeting IGF-1R. The potential application of these inhibitors is currently under intense clinical investigation. This review describes the biology of IGF-1R particularly from a cancer perspective. The attempts to develop effective IGF-1R antagonists are discussed comprehensively with special emphasis on antibodies and small tyrosine kinase inhibitors.
Export Options
About this article
Cite this article as:
Paz Keren and Hadari R. Yaron, Targeted Therapy of the Insulin-Like Growth Factor-1 Receptor in Cancer, Combinatorial Chemistry & High Throughput Screening 2008; 11 (1) . https://dx.doi.org/10.2174/138620708783398313
DOI https://dx.doi.org/10.2174/138620708783398313 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Metallothioneins and Cancer
Current Protein & Peptide Science Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors
Clinical Cancer Drugs The Role of Pemetrexed in Lung Adenocarcinoma, Mixed Subtype with Bronchioloalveolar Carcinoma Features
Current Drug Targets Investigations of Malignant Mesothelioma
Current Respiratory Medicine Reviews Poly (ADP-Ribosyl) Polymerase 1 Inhibitors: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery Progress in Topical siRNA Delivery Approaches for Skin Disorders
Current Pharmaceutical Design Therapeutic Potential of Targeting Glypican-3 in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Inhibition of Disulfide Reductases as a Therapeutic Strategy
Current Enzyme Inhibition Interplay between DNA Methyltransferase 1 and microRNAs During Tumorigenesis
Current Drug Targets EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors
Current Cancer Drug Targets Onconase and Amphinase, the Antitumor Ribonucleases from Rana pipiens Oocytes
Current Pharmaceutical Biotechnology Looking out for Cancer Stem Cells’ Properties: The Value-Driving Role of CD44 for Personalized Medicines
Current Cancer Drug Targets Nanoparticles for Tumor Targeted Therapies and Their Pharmacokinetics
Current Drug Metabolism Membrane Transporters as Determinants of the Pharmacology of Platinum Anticancer Drugs
Current Cancer Drug Targets Using Pharmacologic Data to Plan Clinical Treatments for Patients with Peritoneal Surface Malignancy
Current Drug Discovery Technologies Novel Patents and Cancer Therapies for Transforming Growth Factor- Beta and Urokinase Type Plasminogen Activator: Potential Use of Their Interplay in Tumorigenesis
Recent Patents on Anti-Cancer Drug Discovery Inflammation and Cancer: In Medio Stat Nano
Current Medicinal Chemistry Anti-cancer Immunotoxins, Challenges, and Approaches
Current Pharmaceutical Design Antibody-Drug Conjugate Targets
Current Cancer Drug Targets Systemic Treatment of Chest Tumors: Highlighting Some Differences Between Eastern and Western Countries
Current Cancer Therapy Reviews